Standard Chem & Pharm Co Ltd
TWSE:1720
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60.9
78.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Standard Chem & Pharm Co Ltd
Standard Chem & Pharm Co Ltd
Income from Continuing Operations
Standard Chem & Pharm Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Income from Continuing Operations
NT$1.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
15%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Income from Continuing Operations
NT$1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Income from Continuing Operations
NT$95.3m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Income from Continuing Operations
NT$403m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Income from Continuing Operations
NT$138.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-4%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Income from Continuing Operations
NT$4B
|
CAGR 3-Years
42%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
Standard Chem & Pharm Co Ltd
Glance View
Standard Chemical & Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese and western medicine, medicine raw materials, and health food. The company is headquartered in Tainan, Tainan. The Company’s products cover drugs for circulation systems, digest systems, respiratory systems, nervous systems and other diseases. Through its subsidiaries, the Company is also engaged in the sales of medical equipment, animal medicine, milk powder, cosmetics and others. The firm distributes its products both in domestic markets and overseas markets.
See Also
What is Standard Chem & Pharm Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.2B
TWD
Based on the financial report for Jun 30, 2024, Standard Chem & Pharm Co Ltd's Income from Continuing Operations amounts to 1.2B TWD.
What is Standard Chem & Pharm Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
15%
Over the last year, the Income from Continuing Operations growth was -1%. The average annual Income from Continuing Operations growth rates for Standard Chem & Pharm Co Ltd have been 17% over the past three years , 20% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
